As a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.
Read MoreMcGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.
Read More